Rigel Pharmaceuticals (RIGL) Stock Price, News & Analysis

Company Overview

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for immune and hematologic disorders. The company was founded in 1996 and is headquartered in South San Francisco, California. Its research programs have historically centered on signaling pathways involved in inflammation, autoimmune disease and cancer.

Rigel’s principal commercial product is Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase inhibitor approved in the United States for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Tavalisse is also marketed in certain international markets under the name Tavlesse, with regional commercialization supported by licensing and collaboration arrangements.

The company has also expanded its oncology portfolio through rights to Rezlidhia (olutasidenib), an oral targeted therapy approved in the United States for adults with relapsed or refractory acute myeloid leukemia featuring a susceptible IDH1 mutation. Rigel continues to pursue additional product opportunities in hematology, oncology and immune-mediated diseases. Raul Rodriguez serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $47.49 to $49.65
• 50-Day Range: $36.74 to $49.42
• 52-Week Range: $24.95 to $52.24
• Volume: 69,534 shs
• Average Volume: 358,641 shs
• Market Capitalization: $916.49 million
• P/E Ratio: 3.04
• Dividend Yield: N/A
• Price Target: $59.00
• Consensus Rating: Moderate Buy

Rigel Pharmaceuticals Stock Analysis - MarketRank™

Rigel Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 108th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rigel Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

Rigel Pharmaceuticals has a consensus price target of $59.00, representing about 21.2% upside from its current price of $48.67.

Amount of Analyst Coverage

Rigel Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 44.97%

Earnings Growth

Earnings for Rigel Pharmaceuticals are expected to grow by 44.97% in the coming year, from $2.98 to $4.32 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rigel Pharmaceuticals is 2.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rigel Pharmaceuticals is 2.98, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.03.

Price to Book Value per Share Ratio

Rigel Pharmaceuticals has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.27% of the float of Rigel Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rigel Pharmaceuticals has a short interest ratio ("days to cover") of 15.83, which indicates bearish sentiment.

Change versus previous month

Short interest in Rigel Pharmaceuticals has recently increased by 0.30%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rigel Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rigel Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.20

News Sentiment

Rigel Pharmaceuticals has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Rigel Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for RIGL on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

11 people have added Rigel Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.47% of the stock of Rigel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/28/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RIGL
• CIK: 1034842
• Web: www.rigel.com
• Phone: (650) 624-1100
• Fax: 650-624-1101
• Employees: 174
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Rigel Pharmaceuticals: $59.00
• High Price Target: $85.00
• Low Price Target: $38.00
• Potential Upside/Downside: +19.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $16.32
• Trailing P/E Ratio: 3.03
• Forward P/E Ratio: 16.63
• P/E Growth: N/A
• Net Income: $367.02 million
• Net Margins: 116.30%
• Pretax Margin: 30.92%
• Return on Equity: 22.95%
• Return on Assets: 17.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.94
• Quick Ratio: 1.79

Sales & Book Value

• Annual Sales: $294.28 million
• Price / Sales: 3.12
• Cash Flow: $6.93 per share
• Price / Cash Flow: 7.15
• Book Value: $21.57 per share
• Price / Book: 2.30

Miscellaneous

• Outstanding Shares: 18,500,000
• Free Float: 16,565,000
• Market Cap: $916.99 million
• Optionable: Optionable
• Beta: 1.20